Umeclidinium bromide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Umeclidinium bromide
Umeclidinium bromide.svg
Systematic (IUPAC) name
Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
Clinical data
Trade names Incruse Ellipta
  • US: C (Risk not ruled out)
Routes of
Inhalation (DPI)
Legal status
Legal status
Pharmacokinetic data
Protein binding ~89%[1]
Metabolism Hepatic (CYP2D6)
Biological half-life 11 hours
Excretion Feces (58%) and urine (22%)
CAS Number 869113-09-7
ATC code R03BB07 (WHO)
R03AL03 (WHO) (+vilanterol)
PubChem CID 11519069
ChemSpider 9693857
Synonyms GSK573719A
Chemical data
Formula C29H34BrNO2
Molar mass 508.49 g/mol

Umeclidinium bromide (trade name Incruse Ellipta, GSK) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).[2][3]

External links[edit]


  1. ^ a b "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016. 
  2. ^ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. 
  3. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.